tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris-Stiff G et al. | Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. | 1998 | Transplant. Proc. | pmid:9636525 |
| Woodle ES et al. | Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. | 1998 | Transplant. Proc. | pmid:9636526 |
| Undre NA et al. | Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636527 |
| Kumar MS et al. | ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. | 1998 | Transplant. Proc. | pmid:9636549 |
| Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
| Fitzsimmons WE et al. | Demographic considerations in tacrolimus pharmacokinetics. | 1998 | Transplant. Proc. | pmid:9636552 |
| Shapiro R et al. | Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636557 |
| Grewal HP et al. | Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636558 |
| Rossi G et al. | Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. | 1998 | Transplant. Proc. | pmid:9636562 |
| Samuel D et al. | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636563 |
| McDiarmid S et al. | One hundred children treated with tacrolimus after primary orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636564 |
| Wiesner RH | Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. | 1998 | Transplant. Proc. | pmid:9636565 |
| Van Buren D et al. | Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). | 1998 | Transplant. Proc. | pmid:9636566 |
| Jain A et al. | Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. | 1998 | Transplant. Proc. | pmid:9636567 |
| Zervos XA et al. | Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636568 |
| Millis JM et al. | Successful use of tacrolimus for initial rejection episodes after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636569 |
| Platz KP et al. | FK506 for primary and rescue therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636570 |
| Taibi A et al. | Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. | 1998 | Transplant. Proc. | pmid:9636571 |
| Cai TH et al. | Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636572 |
| Ringe B et al. | Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. | 1998 | Transplant. Proc. | pmid:9636573 |
| Rudich SM et al. | Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636574 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. | 1998 | Transplant. Proc. | pmid:9636575 |
| Bilbao I et al. | Experience with neoral cyclosporine through the oral route in liver transplantation. | 1998 | Transplant. Proc. | pmid:9636580 |
| Langrehr JM et al. | Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636583 |
| Abe M et al. | Successful prednisone withdrawal after living-related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636584 |
| Klupp J et al. | Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636585 |
| Steinmueller T et al. | Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. | 1998 | Transplant. Proc. | pmid:9636589 |
| Liu WT et al. | In vitro generation of tacrolimus metabolites and their detection in whole blood. | 1998 | Transplant. Proc. | pmid:9636590 |
| Bekersky I et al. | Bioequivalence of a new strength tacrolimus capsule under development. | 1998 | Transplant. Proc. | pmid:9636591 |
| Cantarovich M et al. | Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. | 1998 | Transplant. Proc. | pmid:9636592 |
| Mueller AR et al. | Does initial graft function influence the outcome after liver transplantation? | 1998 | Transplant. Proc. | pmid:9636594 |
| Lang M et al. | Impact of immunosuppression in liver transplantation across a positive crossmatch. | 1998 | Transplant. Proc. | pmid:9636595 |
| Platz KP et al. | Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. | 1998 | Transplant. Proc. | pmid:9636596 |
| Ghobrial RM et al. | Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. | 1998 | Transplant. Proc. | pmid:9636597 |
| Nakamura M et al. | Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636600 |
| Charco R et al. | Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636605 |
| Maggard M et al. | Incidence of acute rejection in African-American liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9636607 |
| Mueller AR et al. | Influence of immunosuppression on patient outcome after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636608 |
| McAlister VC et al. | Cost of liver transplantation using tacrolimus. | 1998 | Transplant. Proc. | pmid:9636611 |
| Lipson DA et al. | Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. | 1998 | Transplant. Proc. | pmid:9636612 |
| Wiebe K et al. | FK506 rescue therapy in lung transplantation. | 1998 | Transplant. Proc. | pmid:9636613 |
| Walker S et al. | Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. | 1998 | Transplant. Proc. | pmid:9636618 |
| Schulz T et al. | Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. | 1998 | Transplant. Proc. | pmid:9636623 |
| Ciancio G et al. | Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636624 |
| Bruce DS et al. | Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636625 |
| Peddi VR et al. | Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636626 |
| Burke GW et al. | Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. | 1998 | Transplant. Proc. | pmid:9636627 |
| Gruessner RW | Antibody induction therapy in pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636632 |
| Stratta RJ | Late acute rejection episodes after vascularized pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636633 |
| Goulet O et al. | Small bowel transplantation alone or with the liver in children: changes by using FK506. | 1998 | Transplant. Proc. | pmid:9636636 |